Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
neoplastic disease
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "neoplastic disease" in MCE Product Catalog:
Cat. No.: HY-P99452
CAS No.: 2155851-88-8
Synonyms: SNDX-6352
Target:
Research Areas:
Cat. No.: HY-43521
CAS No.: 1710768-30-1
Research Areas:
Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .
Cat. No.: HY-W009776
CAS No.: 38937-66-5
Synonyms: Suberohydroxamic acid; SBHA
Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .
Cat. No.: HY-176463
CAS No.: 457940-87-3
Nek2/Hec1-IN-3 (Compound 11-28) is a Hec1/Nek2 interaction inhibitor. Nek2/Hec1-IN-3 disrupts Nek2/Hec1 binding and can be used for research of neoplastic diseases .
Target:
Research Areas:
Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and proteasome inhibitor (Kis of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases .
Cat. No.: HY-135382
CAS No.: 2374122-27-5
Target:
Research Areas:
PROTAC IRAK4 degrader-2 is a PROTAC degrader targeting IRAK4. PROTAC IRAK4 degrader-2 induces proteasome-dependent degradation of IRAK4 by recruiting the VHL E3 ligase. PROTAC IRAK4 degrader-2 inhibits multiple cytokines in peripheral blood mononuclear cells. PROTAC IRAK4 degrader-2 can be used in the research of autoimmune diseases, inflammatory diseases and neoplastic diseases .
Cat. No.: HY-141431
CAS No.: 2503325-21-9
Target:
Research Areas:
Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent .
Cat. No.: HY-143208
CAS No.: 2641500-83-4
Target:
Research Areas:
HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt has inhibitory activity against pre-miR-21 RNA. HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt has the potential for the research of neoplastic disease such as cancer and especially cancers expressing miR-21 (extracted from patent WO2021087084A1, compound 25) .
Cat. No.: HY-10132
CAS No.: 1170689-68-5
CASP3 activator 1 is an activator of executioner procaspases 3, 6 and 7. CASP3 activator 1 can be used for the research of cancer, neoplastic diseases .
Cat. No.: HY-182375
CAS No.: 2764877-97-4
Target:
Research Areas:
(R)-SLB1122168 free base, an isomer of SLB1122168 free base (HY-182375A), is a spinster homolog 2 (SPNS2) inhibitor with an IC50 ≤2 μM .
Cat. No.: HY-182375A
CAS No.: 2764877-95-2
Target:
Research Areas:
SLB1122168 free base is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 free base inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC50 of 94 nM. SLB1122168 free base induces lymphopenia in circulating lymphocytes in mice and rats .
Cat. No.: HY-184107
CAS No.: 2290611-27-5
Target:
Research Areas:
Bcl-2-IN-25 is an orally active Bcl-2 inhibitor that induces cytotoxic activity in cancer cells. Bcl-2-IN-25 can be used in cancer-related research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
